Hospira to fund $2M loan to Javelin

Jun 7 2010

Javelin Pharmaceuticals, Inc. (NYSE -- Amex: JAV) ("Javelin") today announced that on June 4, 2010, Javelin received notice from Hospira, Inc. ("Hospira") that Hospira will fund a $2 million loan to Javelin on June 10, 2010 under the existing loan agreement between Javelin and Hospira.

Javelin was also informed on June 4, 2010 that the Delaware Court of Chancery has granted Javelin's motion to expedite proceedings, and a trial date of July 26, 2010 has been set for the lawsuit filed by Javelin against Hospira and its wholly owned subsidiary, Discus Acquisition Corporation ("Discus"), seeking to compel Hospira and Discus to complete the agreed-upon merger pursuant to the definitive merger agreement among Javelin, Hospira and Discus dated April 17, 2010.

Source:

 Javelin Pharmaceuticals, Inc.

Posted in:

Comments (0)

Suggested Reading

Pharmacists stockpile most common drugs on chance of targeted Trump tariffs
Experimental ALS drug shows unprecedented recovery in some patients
How Fluidics is Powering Modern Healthcare and Medical Device Innovation
Trump exaggerates speed and certainty of prescription drug price reductions
New center in Copenhagen to pioneer the future of protein design
New cases of dementia decline while prevalence continues to increase due to population aging
New lab method accelerates diagnosis of genetic disorders of the immune system
Study finds significant uptick in chronic digestive disorders during COVID-19 pandemic

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New injection therapy can lead to long lasting blood pressure reduction